Sunrest Lifescience has filed its audited annual results for the financial year ended March 31, 2025, reporting a significant expansion in its balance sheet size. The company's total assets reached ₹3515.71 lacs, up from ₹2515.55 lacs in the previous year, driven primarily by increases in current assets and non-current liabilities. The filing, signed by statutory auditors Madhusudan C Mashruwala & Co., details the financial position as of March 31, 2025.

The shareholders' funds strengthened during the year, with reserves and surplus rising to ₹1189.40 lacs compared to ₹989.42 lacs in the prior year. Share capital remained constant at ₹429.12 lacs. On the liabilities side, long-term borrowings increased substantially to ₹408.28 lacs from ₹346.18 lacs, while short-term borrowings were recorded at ₹208.02 lacs.

Current assets, which form a major portion of the balance sheet, totaled ₹2826.38 lacs. This included trade receivables of ₹1901.10 lacs and inventories valued at ₹678.51 lacs. Cash and cash equivalents stood at ₹27.90 lacs, while short-term loans and advances amounted to ₹176.91 lacs.

Non-current assets were reported at ₹689.32 lacs, comprising property, plant, and equipment at ₹551.98 lacs. The company also reported non-current investments of ₹2.38 lacs. The total equity and liabilities for the year stood at ₹3515.71 lacs, matching the total assets figure.

The balance sheet was approved by the board and signed by Soham Ushir Mashruwala, Partner at Madhusudan C Mashruwala & Co., and the company's Chairman and Managing Director. The report was filed from Ahmedabad on May 30, 2025.

Financial Summary for FY25

The following table outlines the key financial figures reported by Sunrest Lifescience for the year ended March 31, 2025, compared to the previous year.

Sunrest Lifescience reported a consolidated net profit of ₹411.63 lakh for the financial year ended March 31, 2026, a significant increase from ₹200.56 lakh in the previous year. The company’s consolidated revenue from operations for FY26 stood at ₹7083.29 lakh, compared to ₹3341.30 lakh in FY25. The board of directors approved the standalone and consolidated audited financial results for the half year and year ended March 31, 2026, during a meeting held on May 29, 2026.

Financial Performance

The consolidated financial results include the performance of subsidiary Hetvi Lifesciences Private Limited. For the year ended March 31, 2026, the company reported a total income of ₹7333.97 lakh. Profit before tax for the period was ₹1010.32 lakh, with a total tax expense of ₹210.88 lakh. The statutory auditors, Madhusudan C Mashruwala & Co, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.

Standalone Results

On a standalone basis, Sunrest Lifescience reported a net profit of ₹308.86 lakh for FY26, up from ₹199.98 lakh in the previous year. Revenue from operations for the standalone entity increased marginally to ₹3326.05 lakh from ₹3312.24 lakh in FY25. Total expenses for the year were ₹2918.34 lakh, a decrease from ₹3051.45 lakh in the prior year.

Key Standalone Metrics (FY26)

Board Decisions

In addition to approving the financial results, the board appointed M/S. VRCA & Associates as the internal auditor for the financial year 2026-27, based on the recommendation of the audit committee. The firm registration number is 104727W. The company has not adopted Indian Accounting Standards (Ind AS) due to the exemption available to companies listed on the EMERGE Platform of NSE.